File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

TitleLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Authors
Baselga, JBradbury, IEidtmann, HDi Cosimo, Sde Azambuja, EAura, CGomez, HDinh, PFauria, KVan Dooren, VAktan, GGoldhirsch, AChang, TWHorvath, ZCoccia-Portugal, MDomont, JTseng, LMKunz, GSohn, JHSemiglazov, VLerzo, GPalacova, MProbachai, VPusztai, LUntch, MGelber, RDPiccart-Gebhart, MNeoALTTO Study Team,Kwong, A
Issue Date2012
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 2012, v. 379 n. 9816, p. 633-640 How to Cite?
DOI: http://dx.doi.org/10.1016/S0140-6736(11)61847-3
Persistent Identifierhttp://hdl.handle.net/10722/146915
ISI Accession Number ID
WOS:000300629000034
Funding AgencyGrant Number
GlaxoSmithKline
Roche
Novartis
Amgen
Abbott
AstraZeneca
Pfizer
Sanofi
Bristol-Myers Squibb
Funding Information:

JB has received honoraria from Roche. IB's institution has received funding from GlaxoSmithKline and Roche. HE has been a speaker and received travel grants from GlaxoSmithKline. SDC has been a speaker for GlaxoSmithKline. EdA has served on an advisory board and received a travelling grant from GlaxoSmithKline, and has been a speaker for Roche. KF's institution has received travelling grants from GlaxoSmithKline. VVD's and T-WC's institutions have received research funding from GlaxoSmithKline. AG has received honoraria from GlaxoSmithKline and Roche. T-WC has been a speaker for GlaxoSmithKline, Roche, Novartis, and Amgen; and has received consultancy funding from GlaxoSmithKline, Roche, Abbott, AstraZeneca, Novartis, and Amgen. LP has received consultancy fees from Pfizer, Sanofi, and Bristol-Myers Squibb; and research grants from Bristol-Myers Squibb and AstraZeneca. RDG's institution has received research funding from GlaxoSmithKline and Roche. MP-G has received honoraria from GlaxoSmithKline and Roche, and her institution has received research funding from GlaxoSmithKline. GA is a salaried employee of GlaxoSmithKline and retains stock and stock options at the company. The other authors declare that they have no conflicts of interest.

 

DC FieldValueLanguage
dc.contributor.authorBaselga, Jen_US
dc.contributor.authorBradbury, Ien_US
dc.contributor.authorEidtmann, Hen_US
dc.contributor.authorDi Cosimo, Sen_US
dc.contributor.authorde Azambuja, Een_US
dc.contributor.authorAura, Cen_US
dc.contributor.authorGomez, Hen_US
dc.contributor.authorDinh, Pen_US
dc.contributor.authorFauria, Ken_US
dc.contributor.authorVan Dooren, Ven_US
dc.contributor.authorAktan, Gen_US
dc.contributor.authorGoldhirsch, Aen_US
dc.contributor.authorChang, TWen_US
dc.contributor.authorHorvath, Zen_US
dc.contributor.authorCoccia-Portugal, Men_US
dc.contributor.authorDomont, Jen_US
dc.contributor.authorTseng, LMen_US
dc.contributor.authorKunz, Gen_US
dc.contributor.authorSohn, JHen_US
dc.contributor.authorSemiglazov, Ven_US
dc.contributor.authorLerzo, Gen_US
dc.contributor.authorPalacova, Men_US
dc.contributor.authorProbachai, Ven_US
dc.contributor.authorPusztai, Len_US
dc.contributor.authorUntch, Men_US
dc.contributor.authorGelber, RDen_US
dc.contributor.authorPiccart-Gebhart, Men_US
dc.contributor.authorNeoALTTO Study Team,en_US
dc.contributor.authorKwong, Aen_US
dc.date.accessioned2012-05-23T05:49:32Z-
dc.date.available2012-05-23T05:49:32Z-
dc.date.issued2012en_US
dc.identifier.citationLancet, 2012, v. 379 n. 9816, p. 633-640en_US
dc.identifier.urihttp://hdl.handle.net/10722/146915-
dc.languageengen_US
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet-
dc.relation.ispartofLanceten_US
dc.titleLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialen_US
dc.typeArticleen_US
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0140-6736(11)61847-3-
dc.identifier.pmid22257673-
dc.identifier.scopuseid_2-s2.0-84857236823-
dc.identifier.hkuros199612en_US
dc.identifier.volume379en_US
dc.identifier.issue9816en_US
dc.identifier.spage633en_US
dc.identifier.epage640en_US
dc.identifier.isiWOS:000300629000034-
dc.publisher.placeUnited Kingdom-
dc.identifier.citeulike10246319-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats